Exelixis, an oncology-focused biotechnology company, entered into a clinical trial collaboration and supply agreement with Germany-based Merck KGaA, a science and technology company, …
Since 1986, Farallon Capital has built a proven record for success, mainly from steady hands at the helm and consistent returns for investors. …
Exelixis, Inc. (NASDAQ:EXEL) said on Tuesday that the FDA approved its CABOMETYX tablets, for the expanded indication of patients with advanced renal cell carcinoma …
Sean Lavin: TRXC investor focus to turn to U.S.
Cowen’s Eric Schmidt sees an extra several hundred million dollars in sales for EXEL in HCC market.
Exelixis, Inc. (NASDAQ:EXEL) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 30% upturn.
A first glance at this hedge fund’s strategic Q2 moves in biotech sector.
Exelixis, Inc. (NASDAQ:EXEL) announced this morning that it has completed the submission of a supplemental New Drug Application (sNDA) to FDA for Cabometyx …
Dynavax’s Advantage Weighs Towards Heplisav’s Benefits Dynavax Technologies Corporation (NASDAQ:DVAX) shares are racing 5% today after releasing second-quarter earnings. However, this rocket momentum …
Sarepta’s $12+ Million 2Q Beat Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech …